Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION
STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS
12 FEBRUARY 2025 at 21.00 EET

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 11 February 2025 above five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

	% of shares and voting rights (total of point A)	% of shares and voting rights through financial instruments (total of point B)	Total of both in % (points A + B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	5.00% shares Below 5% voting rights	N/A shares Below 5% voting rights	5.00% shares Below 5% voting rights	141,134,278 shares 763,427,275 voting rights
Position of previous notification (if applicable)	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI0009014377		7,066,630 shares Below 5% voting rights		5.00% shares Below 5% voting rights
POINT A SUBTOTAL	7,066,630 shares Below 5% voting rights		5.00% shares Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument	Expiration date	Exercise / Conversion Period	Physical or cash settlement	Number of shares and voting rights	% of shares and voting rights
			POINT B SUBTOTAL

Orion Corporation

Liisa Hurme
President and CEO

Olli Huotari
SVP, Corporate Functions

Contact person:
Tuukka Hirvonen, Investor Relations

tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.